


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61M 1/36, A61L 2/00	A1	(11) International Publication Number: WO 97/46271 (43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/GB97/01454 (22) International Filing Date: 29 May 1997 (29.05.97) (30) Priority Data: 9611698.3 5 June 1996 (05.06.96) GB (71) Applicant (for all designated States except US): IATROS LIMITED [GB/GB]; Saltire Court, 20 Castle Terrace, Edinburgh EH1 2EN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): MOWAT, David, McIvor [GB/GB]; 37 Orchard Road South, Edinburgh EH4 3JA (GB). CAMERON, Ian, David [GB/GB]; 10 Macnabb Street, Dundee DD4 7EH (GB). GUNN, Andrew [GB/GB]; Kirkden House, Letham, Angus DD8 2QF (GB). (74) Agents: McCALLUM, William, Potter et al.; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>

(54) Title: IRRADIATION DEVICE AND METHOD FOR FLUIDS ESPECIALLY FOR BODY FLUIDS



(57) Abstract

The present invention relates to a device (1) suitable for use in the sterilization of a fluid (17) such as a biological fluid or a fraction thereof, containing lymphocytes and/or micro-organisms. The device (1) comprises a vessel (2) having an inlet (4) and an outlet (5) and a passage (3) which extends non-tortuously therebetween. The passage (3) has a heat exchange device (14) with a heat exchange surface (10) in substantial direct thermal contact with the interior of the passage (3). A temperature control means (7) is formed and arranged to maintain temperature of fluid (17) in the passage (3) below a temperature at which fluid (17) components may form insoluble particles during irradiation. The passage (3) has a wall which is substantially transparent to a lymphocyte and/or micro-organism inactivating radiation (20). The passage (3) contains a static mixer device (6) which is formed and arranged for thoroughly mixing the fluid (17) in use of the device so as to bring substantially the whole of the fluid (17) into an irradiation zone (19) extending along and in substantially direct proximity to the passage walls (3) during passage between the inlet (4) and the outlet (5) and into contact with the heat exchange surface (10). In use of the device (1) substantially the whole of a body of fluid to be sterilized passes through the vessel (2) and may be exposed to a similar substantial level of irradiation whilst maintaining it at a safe temperature.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IRRADIATION DEVICE AND METHOD FOR FLUIDS ESPECIALLY FOR BODY FLUIDS

The present invention relates to the treatment of biological fluids, especially body fluids, and fractions thereof to inactivate selected components, e.g. lymphocytes, and micro-organisms, including viruses and the like, in human blood and in particular to a device suitable for use in such a procedure.

Large amounts of body fluids such as blood and plasma and various fractions thereof are used in the treatment of patients suffering from a variety of conditions. Contamination of such fluids with various viruses and other microorganisms however can give rise to serious new conditions in the patients receiving these fluids and may even result in their death.

Although it has been known for some time that ultra-violet (UV) irradiation can inactivate lymphocytes and viruses, this was not a practical procedure because of the very low UV transmissibility of blood and hence the difficulty of ensuring a complete irradiation and inactivation. More recently we have considerably reduced this problem in our Patent No. GB 2200020 with the use of static mixers which provided a very thorough mixing of the fluid during irradiation thereby permitting a substantially even irradiation of the whole of the fluid.

We have now found, that fluids containing fibrinogen are susceptible to activation and formation of more or less large particles of polymeric fibrin. Such particles can moreover form around viruses and other microorganisms and thus screen them from the UV radiation thereby preventing inactivation thereof, and thus seriously risking the health of the recipient of the treated fluid. This fibrinogen activation can be readily triggered by mechanical stress e.g. shear forces present in mixing and by heat which can readily occur locally during irradiation. Insoluble particles of material

-2-

can also be formed by thermal and/or mechanical denaturation of other proteinaceous components.

Such problems also arise with conventional sterilization of human blood products which generally involves incubation thereof at a temperature of the order of 78°C for an extended period of time of perhaps 48 to 72 hours. This procedure further has the disadvantages of being relatively time consuming and occupying substantial amounts of relatively large scale apparatus and may result in substantial loss of potency.

It is an object of the present invention to avoid or minimize one or more of the above disadvantages.

We have now found that by carefully controlling the temperature of the fluid and preventing any localized heating thereof, formation of particles which can screen viruses and other microorganisms from inactivating radiation, can be substantially prevented.

In one aspect the present invention provides a device suitable for use in the sterilization of a fluid, which is a biological fluid or a fraction thereof, containing lymphocytes and/or micro-organisms, which device comprises a vessel having an inlet and an outlet and a passage means extending substantially directly and non-tortuously therebetween, said passage means having a heat exchange device with a heat exchange surface in substantially direct thermal contact with the interior of the passage means, and a temperature control means formed and arranged for maintaining the temperature of fluid in the passage below a temperature at which fluid components may form insoluble particles during irradiation, and said passage means having wall means substantially transparent to a lymphocyte and/or micro-organism inactivating radiation, said passage means containing a static mixer device formed and arranged for thoroughly mixing the fluid in use of the device, so as to

-3-

bring substantially the whole of the fluid into an irradiation zone extending along and in substantially direct proximity to said wall means during passage between said inlet and said outlet and into contact with said heat exchange surface, whereby in use of the device substantially the whole of a body of said fluid passed through said vessel may be exposed to a similar substantial level of irradiation whilst maintaining it at a safe temperature.

10 Thus with a device of the present invention a particularly uniform treatment of the fluid with respect to both irradiation and temperature thereof may be achieved thereby avoiding on the one hand under-exposure to inactivating radiation whether as a result of screening by an excessive

15 depth of soluble fluid components or by enveloping insoluble material formed by more or less direct thermal denaturation of fluid components or as a result of thermally and/or mechanically triggered reactions (such as fibrinogen activation), as well as avoiding localized overheating

20 induced by the irradiation which can result in reduced inactivation and/or increased degradation, thereby on the one hand maximizing inactivation of lymphocytes (where required) and/or undesirable microorganisms and on the other hand minimizing denaturation and degradation of useful fluid

25 components.

It will be appreciated that various forms of heat exchange device may be used including solid state devices such as Peltier effect devices. Conveniently though there is used a

30 heat exchange device wherein is circulated a heat exchange fluid (e.g. gas, liquid, or liquid mixed with gas and/or frozen liquid) as this generally facilitates more precise control of the biological fluid temperature.

35 Conveniently there is used an annular form of vessel with an outer wall substantially transparent to lymphocyte and/or microorganism inactivating radiation and an inner wall constituting said heat exchange surface, the latter

-4-

- preferably being of a generally inert physiologically compatible material with high thermal conductivity e.g. stainless steel. Any suitable heat exchange fluid may be used e.g. water. Where a heat exchange fluid is used then the temperature of this may be controlled in various ways remotely from said heat exchange surface in the vessel e.g. using a solid state heat exchanger such as a Peltier-effect heat pump or a refrigeration coil etc.
- 10 Various forms of temperature control means may be used. In general there is used a variable rate cooling device provided with a controller for varying the cooling rate according to an input from a temperature sensor means disposed in thermal connection with at least one of the fluid passage means, the heat exchange surface, and a heat exchange fluid passage in said heat exchange device.

- It will be appreciated that the "safe" temperature limits for avoiding denaturation and/or other thermally triggered reaction may vary from one biological fluid or fraction thereof to another, and also depending on the application of the fluid, and conveniently there is used a temperature control means which allows for the fluid temperature to be maintained at a plurality of different values as required.
- 20 In general for any body fluids containing fibrinogen the temperature is desirably maintained at not more than 37°C, preferably from -5 to 37°C, advantageously from -5 to 19°C.

- In a preferred aspect of the invention the device includes at least one microorganism inactivating radiation source mounted in more or less closely spaced proximity to said transparent wall means (for the avoidance of doubt it should be noted that references to the transparent wall means merely indicates substantial transmission of the inactivating radiation which may or may not be accompanied by significant transparency at other wavelengths e.g. visible light). The mounting of the radiation source is generally arranged to minimize undesired heating of the transparent wall means and

-3-

biological fluid in contact therewith whilst maximizing the radiation intensity in the irradiation zone. Depending on the source used this is generally positioned at from 1.5 to 5mm from the transparent wall.

5

Various lymphocyte and/or microorganism inactivating radiations may be used, though UV is generally preferred, especially UV radiation having a wavelength range from 100 to 400 nm preferably from 200 to 350 nm, for example UVA at approximately 320 to 400 nm. UVB at approximately 310 nm and UVC at approximately 254 nm.

Suitable UV lamp sources are readily available commercially. Particular lamp sources which may be mentioned include those available from GTE Sylvania Ltd. of Charlestown, Shipley, West Yorkshire. Thorn EMI of Enfield, Middlesex and Philips Lighting of Croydon, Surrey, all in United Kingdom.

It should also be noted that the present invention also includes within its scope indirect inactivation of microorganism whereby a photoactivatable drug is incorporated in the fluid, said drug being converted from a non-activating form into a microorganism inactivating form by U.V. irradiation. One example of a photoactivatable drug of this type that may be mentioned is a psoralen e.g. 8-methoxy psoralen which upon exposure to U.V.-A radiation of 320 to 400 nm wavelength becomes capable of forming photoadducts with DNA in lymphocytes thereby inactivating these.

Where UV radiation is used to effect inactivation then the vessel side wall means may be made of various UV - transparent materials including for example silica and other UV - transparent glasses such as those available under the Trade Names Spectrosil and Vitreosil; silicones; cellulose products such as Cellophane (Trade Name); and plastics materials such as polytetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), and preferably low density polyethylene (LDPE) or polyvinyl chloride (PVC).

Other inactivating radiations that may be used include microwave radiation used in conjunction with e.g. a glass or ceramic vessel wall; infra-red radiation used in conjunction with e.g. a quartz vessel wall; ultrasound radiation used in conjunction with e.g. a stainless steel vessel wall.

The duration of irradiation required will depend on various factors such as the intensity, disposition, and number of sources used, the transmission characteristics of the vessel side wall material, the vessel configuration and hence the mixing efficiency therein and the surface area of the thin layer of fluid adjacent the vessel side wall, the length of the passage means in the vessel and the flow-rate of the fluid being treated, and hence the residence time of the fluid in the irradiation zone, as well as the nature of the fluid itself. The required duration may however be readily determined by simple trial and error using suitable techniques known in the art for assessing inactivation of the relevant microorganisms and further details are provided hereinbelow. In general the residence time in the vessel will conveniently be in the range from 5 seconds to 30 minutes, preferably from 30 seconds to 10 minutes, e.g. 2 minutes, and the vessel side wall material and thickness and the radiation sources are chosen and arranged, to provide an effective inactivating dosage of U.V. radiation within such a period.

It will moreover be appreciated that the required irradiation time can be achieved in a number of different ways including one or more of the following: use of vessels with irradiation zones of different length, varying the flow rate of the fluid, using a plurality of devices in series, and recycling the fluid through the device(s) a number of times, though generally it is highly desirable that the inactivation treatment system is designed so that the required level or irradiation is achieved in a single pass, especially where the inactivation treatment system is incorporated in a

-7-

production line for the manufacture of various products e.g. IgG, Factor VIII etc. etc.

Whilst it is a particular advantage of the present invention
5 that denaturation of useful body fluid components is minimized, there can advantageously be included in the body fluid one or more protectants such as rutin, Ascorbic acid (ca 1mM), or Quercetin (ca 0.2 mM), which reduce still further any possible denaturation or degradation of useful
10 components.

It will also be understood that the degree of mixing required to achieve complete irradiation will depend on various factors such as the transmissibility of the fluid to the
15 inactivating radiation and the total depth of fluid in the vessel from the wall through which radiation is received. In general the lower the transmissibility and the greater the fluid depth, the greater will be the number of mixer elements and mixing stages required.

20

Further preferred features and advantages of the invention will appear from the following detailed description given by way of examples and illustrated with reference to the accompanying drawings in which:

25 Fig. 1 is a partly schematic partly sectioned view of an irradiation apparatus of the present invention.

Fig. 1 shows an apparatus 1 comprising a vessel 2 in the form of a cylindrical tube 3 of quartz or other UV- transmissible
30 material with an inlet 4 and an outlet 5, with an axially extending static mixer device 6 provided with temperature control means 7. In more detail the static mixer device 6 comprises an axially extending series of angularly offset helical "screw" elements 8 defining pairs of flow paths which
35 are divided equally and mixed at the junctions 9 between successive elements 8 thereby providing a degree of mixing which increases exponentially with the number of elements used.

-8-

The "screw" elements 8 are mounted on a hollow core 10 which defines a heat exchange fluid passage 11 forming part of the temperature control means 7. In more detail the temperature control means 7 comprises a heat exchange fluid circuit 12 provided with pump means 13 for circulating the heat exchange fluid 12a therethrough and a Peltier-effect heat exchange device 14 provided with a control means 15 which has a temperature sensor 16 mounted inside the vessel 3 for monitoring the temperature of the fluid undergoing irradiation. The control means 15 is formed and arranged for controlling the rate of cooling supplied so as to maintain a desired fluid temperature. This may be a fixed value, or more conveniently the control means 15 may be provided with user operable input means for varying the desired temperature setting.

The core 10 (and desirably also the screw elements 8) are of an inert physiologically acceptable thermally conductive material such as stainless steel in order to facilitate efficient thermal transfer between the fluid being treated 17 and the heat exchange circuit 7 thereby to control the fluid temperature closely within relatively narrow limits so as to on the one hand maximise the efficiency of the sterilization/inactivation treatment and on the other hand to minimize any undesired denaturation or degradation of useful fluid components.

Irradiation 20 is effected by means of a plurality of UVC-emitting fluorescent tubes 21 extending parallel to and closely spaced from the vessel 3 and angularly distributed therearound. Advantageously reflectors 22 are provided to help concentrate the radiation 20 onto the vessel. The irradiation chamber may also be cooled by a fan 23. The vessel 3 is made of quartz in order to maximize transmission of the radiation 20 into the fluid 17 being treated and has diameter of approximately 20mm, and a mixer 6 with a length of 300mm and 10 elements.

-9-

The pump means 13 advantageously is provided with a flow rate controller in order to vary the flow rate of the fluid 12a to adjust the residence time of the fluid in the vessel 3 in the irradiation zone 19 and also to minimize denaturation or degradation of useful fluid components arising from mechanical stress in and around the static mixer 6. In general there may be used a flow rate of the order of 1cm/sec to 100cm/sec preferably 2 cm/sec to 50 cm/sec, desirably from 5 to 20 cm/sec.

It will be appreciated that the vessel 3 and mixer 6 may be found and arranged so that complete irradiation may be achieved with a single pass of the fluid through the vessel. Alternatively though a plurality of passes may be used to achieve full irradiation.

Use of the apparatus will be further explained in the following illustrative example.

20

Example 1 - Treatment of Human Plasma

Irradiation was carried out using an irradiation device having four 500 mm long UVC light sources distributed around 6 mm internal diameter PTFE tube containing a 34 cm long static mixer of the type shown in Fig. 1 with 48 screw elements. The fluid was circulated through the quartz tube, and a cooling device mounted in series therewith, at a flow rate of 100 ml/min which corresponded to an irradiation time of approximately 6.2 seconds for each passage. The fluid was circulated until a total effective irradiation time of approximately 100 seconds was achieved and the temperature thereof maintained at around 6.5°C.

Using plasma samples (200 ml) into which has been introduced a bacteriophage virus (2 ml) selected from: X174 and MS-2 (single-strand DNA and RNA respectively); T4 (double-strand DNA) and PR7772 (double strand DNA, enveloped), a virus kill in the region of 5-6 logs (i.e. over 99.999%) was achieved.

-10-

At the same time the coagulation factor activity of key components of the plasma was substantially maintained as follows:

5	Factor CIII:C	57.3 \pm 4.2%
	Factor V	38.8 \pm 10.4%
	Fibrinogen	63.5 \pm 4.2%
	APTT	18.5 \pm 3.4%

- 10 In a further experiment rutin (1.6 mM) was introduced into the plasma as a protectant and the retained coagulation factor activity was increased to over 85% whilst maintaining the virus inactivation level.

15 Example 2:

Using substantially similar procedures a human immunoglobulin preparation (150g of IgG per litre) containing MS-2 (1.5g) was subjected to an effective irradiation time of 300 seconds.

20

A virus inactivation level of 4.8 logs was achieved whilst aggregate formation increased from an initial level of 7.0% to only 7.6%.

- 25 Sterilization of the blood is monitored by one or more of the following procedures:

- (a) Separation of lymphocytes, culture and subsequent dosage with tritiated thymidine and subsequent liquid scintillation counting.
- 30 (b) Separation of lymphocytes, culture and examination by electron microscope.
- (c) Separation of lymphocytes and observation of response to tissue stains.
- (d) Culture of bacteria by standard laboratory methods.
- 35 (e) Growth of viruses by standard laboratory methods.
- (f) Study of Protozoans by light and electron microscopy and by in vivo passage in an animal species.

-11-

(g) Study of biological behaviors of Blood Platelets by standard in vitro hematological techniques e.g. behavior in an agregometer and after exposure to collagen, ATP etc.

-12-

CLAIMS

1. A device (1) suitable for use in use in the sterilization of a fluid (17), which is a biological fluid or a fraction thereof, containing lymphocytes and/or micro-organisms, which device comprises a vessel (2) having an inlet (4) and an outlet (5) and a passage means (3) extending substantially directly and non-tortuously therebetween, said passage means (3) having a heat exchange device (14) with a heat exchange surface (10) in substantially direct thermal contact with the interior of the passage means (3), and a temperature control means (7) formed and arranged for maintaining the temperature of fluid (17) in the passage (3) below a temperature at which fluid (17) components may form insoluble particles during irradiation, and said passage means (3) having wall means (3) substantially transparent to a lymphocyte and/or micro-organism inactivating radiation (20), said passage means (3) containing a static mixer device (6) formed and arranged for thoroughly mixing the fluid (17) in use of the device, so as to bring substantially the whole of the fluid (17) into an irradiation zone (19) extending along and in substantially direct proximity to said wall means (3) during passage between said inlet (4) and said outlet (5) and into contact with said heat exchange surface (10), whereby in use of the device (1) substantially the whole of a body of said fluid (17) passed through said vessel (2) may be exposed to a similar substantial level of irradiation whilst maintaining it at a safe temperature.
2. A device (1) as claimed in claim 1 wherein said heat exchange device (14) is a solid state Peltier-effect device.
3. A device (1) as claimed in claim 1 wherein said heat exchange device (14) comprises a conduit means (10) for the passage of a heat exchange fluid (12a) through the interior of said static mixer device (6) and in substantially direct thermal contact with an external surface of said static mixer

-13-

device which constitutes said heat exchange surface of said heat exchange device.

4. A device (1) as claimed in any one of claims 1 to 3 wherein said vessel (2) has an annular form with an outer wall substantially transparent to a lymphocyte and/or microorganism inactivating radiation (20) and an inner wall constituting said heat exchange surface (10).
- 10 5. A device (1) as claimed in claim 3 or claim 4 when dependent on claim 3 wherein the temperature of said heat exchange fluid (12a) is controlled (15) remotely from said heat exchange surface (10) in the vessel (2) by means of a solid state heat exchanger (14).
- 15 6. A device (1) as claimed in any one of claims 3, 4 when dependent on claim 3, or 5 wherein said temperature control means (7) is in the form of a variable rate cooling device provided with a controller (15) for varying the cooling rate according to an input from a temperature sensor means (16) disposed in thermal connection with at least one of said fluid passage means (3), said heat exchange surface (10), and the heat exchange fluid passage (11) in said heat exchange device (14).
- 25 7. A device (1) as claimed in any one of claims 1 to 6 for use in the sterilization of a body fluid containing fibrinogen wherein said temperature control means is formed and arranged to maintain the temperature of said body fluid (17) at a temperature in the range of from -5°C to $+37^{\circ}\text{C}$.
- 30 8. A device (1) as claimed in any one of claims 1 to 7 which includes at least one lymphocyte and/or microorganism inactivating radiation source (21) mounted in more or less closely spaced proximity to said transparent wall means (3).
- 35 9. A device (1) as claimed in any one of claims 1 to 8 wherein said lymphocyte and/or microorganism inactivating

-14-

radiation is ultra violet radiation having a wavelength in the range of from 200 to 350 nm.

10. A device (1) as claimed in any one of claims 1 to 9
5 wherein said side wall means (3) of said vessel (2) is made of substantially ultraviolet-transparent materials selected from the group including UV-transparent glasses, silicone, cellulose products, and plastics materials.
- 10 11. A device (1) as claimed in any one of claims 1 to 8 wherein there may be used inactivating radiation and vessel wall material combinations selected from the group including microwave radiation used in conjunction with glass; infra-red radiation used in conjunction with a quartz vessel wall; or
15 ultra sound radiation used in conjunction with a metal vessel wall.
12. A device (1) as claimed in any one of claims 1 to 11 wherein there are provided reflectors (22) spaced around the
20 vessel (2) formed and arranged to concentrate the radiation (20) onto said vessel.
13. A method of sterilizing a biological fluid (17) or fraction thereof, containing lymphocytes and/or micro-
25 organisms comprising the steps of:
providing a device (1) according to claim 1;
providing a lymphocyte and/or microorganism inactivating radiation source (21) in more or less closely spaced proximity to said transparent wall means of said device (1);
30 passing said fluid (17) through said passage means (3) of said device (1) so that the whole of a body of said fluid (17) is exposed to a similar substantial level of lymphocyte and/or microorganism inactivating irradiation; and
operating said temperature control means (7) of said device
35 (1) so as to maintain the temperature of the fluid (17) in the passage means (3) below a temperature at which fluid (17) components may form insoluble particles during irradiation.

-15-

14. A method as claimed in claim 13 which includes the step, prior to passing said fluid (17) through said passage means (3), of incorporating into the fluid (17) to be sterilized a photoactivatable drug, said drug being convertible from a non-activated form into a lymphocyte and/or microorganism-inactivating form by radiation (20).
15. A method as claimed in claim 13 or claim 14 which includes the step, prior to passing said fluid (17) through said passage means, of incorporating into the fluid (17) to be sterilized at least one protectant to reduce further any possible denaturation or degradation of useful fluid components.
16. A method as claimed in any one of claims 13 to 15 wherein the residence time of fluid (17) in said vessel (2) of said device (1) is in the range of from 30 seconds to 10 minutes.

1/1




FIG. 1

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/GB 97/01454

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61M1/36 A61L2/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61M A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 92 11060 A (BAXTER INTERNATIONAL INC.) 9 July 1992 see page 9, line 26 - page 10, line 3 see page 12, line 23 - line 35 see figure 2	
A	US 2 309 124 A (E KNOT) 26 January 1943 -----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

12 September 1997

Date of mailing of the international search report

22.10.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+ 31-70) 340-3016

Authorized officer

Vereecke, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/01454

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9211060 A	09-07-92	AU 646533 B	24-02-94
		AU 9159391 A	22-07-92
		CA 2074806 A	21-06-92
		EP 0525138 A	03-02-93
		JP 5505126 T	05-08-93
		US 5290221 A	01-03-94

US 2309124 A	26-01-43	NONE	
